Stocks Health care AUTL
NASDAQ · Health careAutolus Therapeutics plc (AUTL)
Autolus Therapeutics plc brought in $117.4M of revenue over the twelve months to June 30, 2026, up 292.2% from a year earlier. It posted a net loss of $280.2M. In fiscal 2025 capital spending exceeded operating cash flow by $302.6M. At June 30, 2026 it held $171.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Autolus Therapeutics plc
- Net worth
- Autolus Therapeutics plc has a market value (market cap) of $351.3M at the latest share price, and shareholders' equity of $74.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $75.4M (+644.9% year on year), with a net loss of $287.5M. Over the 12 months to June 30, 2026: revenue $117.4M, net loss $280.2M.
- Cash flow
- In fiscal 2025 operations used $283.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Autolus Therapeutics plc's next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Autolus Therapeutics plc does
Autolus Therapeutics plc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker AUTL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $75.4M | -$287.5M | -$1.08 | -$302.6M |
| 2024 | $10.1M | -$220.7M | -$0.86 | -$228.3M |
| 2023 | $1.7M | -$208.4M | -$1.20 | -$156.6M |
| 2022 | n/a | -$148.8M | -$1.57 | -$123.1M |
| 2021 | n/a | -$142.1M | -$1.97 | -$126.7M |
| 2020 | n/a | -$142.1M | -$2.76 | -$132.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AUTL ranks in Health care
Latest SEC filings
What Autolus Therapeutics plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026Form DEL AM filing DEL AM
- September 14, 2026
- August 28, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 118% to $45.7M versus the same quarter last year; diluted EPS -$0.15 versus -$0.18.
- August 11, 2026
- August 3, 2026
- August 3, 2026
- June 29, 2026
- June 9, 2026Other event 8-K
Insider trades
What the people running Autolus Therapeutics plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $15.7K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Piccina CintiaU.S. CCO & Country Gen Manager | Sold | 6,713 | $15.7K |
| September 1, 2026 | Piccina CintiaU.S. CCO & Country Gen Manager | Exercised options | 20,000 | $47K |
Who owns AUTL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| MAK Capital Fund LP13G, passive with 2 related filers | 12.6% | May 15, 2026 |
| Syncona Portfolio Limited13G, passive with 6 related filers | 10.8% | May 7, 2025 |
| Armistice Capital, LLC13G, passive with 1 related filers | 5.64% | August 14, 2026 |
| Renata Kellnerova13D, may seek influence with 3 related filers | 5.6% | August 28, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 84 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Mak Capital One LLC | 33,621,487 | 0 |
| Blackstone Inc. | 20,485,611 | 0 |
| Syncona Portfolio Ltd | 16,640,720 | 0 |
| Armistice Capital, LLC | 15,000,000 | -800,000 |
| Tetragon Partners GP Ltd | 9,500,000 | 0 |
| Schroder Investment Management Group | 7,833,282 | -1,656,063 |
| Frazier Life Sciences Management, L.P. | 4,447,910 | 0 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3,361,156 | 0 |
| Laurion Capital Management LP | 3,316,626 | 0 |
| Renaissance Technologies LLC | 1,984,700 | -314,799 |
| Bank of America Corp | 1,605,092 | -239,579 |
| BlackRock, Inc. | 1,603,458 | +122,726 |
| UBS Group AG | 1,516,991 | +211,212 |
| Morgan Stanley | 1,260,832 | +319,009 |
| Millennium Management LLC | 1,224,818 | +1,020,090 |
| Cetera Investment Advisers | 1,157,324 | +28,250 |
| Balyasny Asset Management L.P. | 972,748 | +1,057 |
| Jpmorgan Chase & Co | 913,239 | -22,164 |
| Alphabet Inc. | 698,262 | 0 |
| Citadel Advisors LLC | 695,890 | +236,486 |
Insiders
1 insiders reported holding 13,287 shares in total, about $17.5K at the last price.
| Holder | Shares |
|---|---|
| Piccina CintiaU.S. CCO & Country Gen Manager | 13,287 |
Questions about AUTL
What does Autolus Therapeutics plc do?
Autolus Therapeutics plc is a company in the Health care sector, listed on NASDAQ as AUTL. Its shares trade on NASDAQ under the ticker AUTL.
What is Autolus Therapeutics plc's net worth?
Autolus Therapeutics plc has a market value (market cap) of $351.3M at the latest share price, and shareholders' equity of $74.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Autolus Therapeutics plc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $280.2M on revenue of $117.4M.
How much revenue does Autolus Therapeutics plc make?
Over the twelve months to June 30, 2026 Autolus Therapeutics plc reported revenue of $117.4M. That is 292.2% more than a year earlier.
When did Autolus Therapeutics plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form DEL AM filing from September 15, 2026.
When is Autolus Therapeutics plc's next earnings report?
Autolus Therapeutics plc's next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AUTL with
Follow AUTL
Get an email when Autolus Therapeutics plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Autolus Therapeutics plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.